Clinical Trial of Gut Microbiota in the Management of Immune Thrombocytopenia
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, accounting
for about 1/3 of clinical hemorrhagic diseases. Loss of immune tolerance leading to increased
platelet destruction and decreased platelet production is the main pathogenesis of ITP.
Dysbiosis of the gut microbiota was found in many autoimmune diseases like rheumatic
arthritis(RA),inflammatory bowel disease(IBD),multiple sclerosis and probiotic treatment or
fecal microbiota transplantation(FMT) which can regulate the gut microbiota has good clinical
efficacy in those disorders. One ITP patient with ulcerative colitis(UC) was treated with FMT
and got progressive but significant increase in platelet level and lasted for several years.
Phase:
Phase 2
Details
Lead Sponsor:
Shandong University
Collaborators:
Jinan Central Hospital Qianfoshan Hospital Qingdao University The Second Hospital of Shandong University Yantai Yuhuangding Hospital